Obinutuzumab

A4DAB184 | Cancer | Approved
MS4A1/CD20
G1 / IgG1
Approved
Whole mAb
Afutuzumab GA-101 GA101 GA 101 Gazyva Gazyvaro R-7159 R 7159 R7159 RG 7195 RG-7159 RG7159 RO-5072759 RO5072759 RO 5972759
GLYCART Biotechnology Biogen Idec Chugai Pharmaceutical Dana-Farber Cancer Institute Genentech Lymphoma Academic Research Organisation Nippon Shinyaku OHSU Knight Cancer Institute Pharmacyclics Polish Myeloma Consortium Roche Thomas Jefferson University University of Heidelberg University of Leeds
6
IMGT PubChem Thera-SAbDab YAbS
Avg A4D Score
-0.6898
Score Range
-0.72 to -0.62
Structures
5
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB184_3pp4_H_L 3pp4 100% -0.7056 6.5 9.0 -0.3047 -0.759
A4DAB184_3pp3_I_K 3pp3 100% -0.6911 6.5 4.0 -0.2801 -0.7452
A4DAB184_6y97_H_L 6y97 100% -0.62 7.0 4.0 -0.2052 -0.7409
A4DAB184_6y9a_H_L 6y9a 100% -0.7177 6.5 4.0 -0.1953 -0.7867
A4DAB184_3pp3_H_L 3pp3 100% -0.7144 6.5 9.0 -0.2957 -0.7694